Tourmaline Bio
Tourmaline Bio is a late-stage clinical biotechnology company whose lead program is TOUR006, a naturally long-half-life anti-IL-6 antibody.
- Acquired, subsidiary of Novartis
- New York, NY, USUnited States
Tourmaline Bio is a late-stage clinical biotechnology company whose lead program is TOUR006, a naturally long-half-life anti-IL-6 antibody.
Novartis acquires Tourmaline Bio, integrating the biotech firm as a wholly owned subsidiary. The deal aligns with Novartis’s strategy to expand expertise in targeted therapeutic areas. Tourmaline’s shares cease trading on Nasdaq following the completion of the transaction.
Oct 2025NovartisNews article
Novartis acquires Tourmaline to bolster its immunology drug pipeline. The company also introduces a direct-to-patient (DTP) distribution model to streamline drug manufacturing and delivery processes. These moves aim to enhance efficiency and accessibility in drug production and distribution.
Sep 2025biopharminternational.comNews article
Novartis acquires Tourmaline Bio for **$1.4 billion**, gaining **pacibekitug**, a Phase 3-ready antibody drug targeting **atherosclerotic cardiovascular disease (ASCVD)**. The drug was originally licensed from **Pfizer**, which retains milestone payment eligibility based on development progress. This move positions Novartis to compete with **Novo Nordisk** and **CSL** in cardiovascular treatments.
Sep 2025MedCity NewsNews article
Novartis AG has agreed to acquire **Tourmaline Bio** in an all-cash deal valued at approximately **$1.4 billion** for **$48.00 per share**. The transaction aligns with Novartis’s strategy to expand its biopharmaceutical portfolio. Tourmaline Bio specializes in developing novel therapies for rare diseases, including its lead asset targeting **autoimmune disorders**. The acquisition follows Tourmaline’s progress in clinical-stage programs and aims to accelerate Novartis’s pipeline in high-unmet-need areas.
Sep 2025GlobeNewswireNews article